Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
May 13, 2024 07:00 ET
|
Entera Bio Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
May 13, 2024 04:00 ET
|
Macomics Limited
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe...
PBC BioVet: Eine neue Dimension in der tierärztlichen Versorgung
May 12, 2024 20:05 ET
|
PBC Biomed Ltd
SHANNON, Irland, May 13, 2024 (GLOBE NEWSWIRE) -- PBC Biomed ist stolz darauf, sein neuestes Unternehmen, PBC BioVet, vorzustellen: eine engagierte Tochtergesellschaft, die darauf abzielt, die...
Présentation de PBC BioVet : une nouvelle frontière dans les soins de santé vétérinaires
May 12, 2024 20:05 ET
|
PBC Biomed Ltd
SHANNON, Irlande, 13 mai 2024 (GLOBE NEWSWIRE) -- PBC Biomed est fier de dévoiler son tout nouveau projet, PBC BioVet, une filiale entièrement dédiée aux soins vétérinaires. Fermement résolu à...
Introducing PBC BioVet: A New Frontier in Veterinary Healthcare
May 12, 2024 20:05 ET
|
PBC Biomed Ltd
SHANNON, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- PBC Biomed is proud to unveil its latest venture, PBC BioVet, a dedicated affiliate aimed at revolutionizing veterinary healthcare. With a...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
May 10, 2024 16:10 ET
|
Entera Bio Ltd.
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
May 10, 2024 07:55 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024 07:45 ET
|
Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024 16:05 ET
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 09, 2024 16:01 ET
|
MacroGenics, Inc.
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09,...